Nektar Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

DB:ITH Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
24 Dec 24	Sell€14,186	Mark Wilson	Individual	16,560	€0.86
23 Dec 24	Sell€28,913	Mark Wilson	Individual	33,402	€0.87
19 Dec 24	Sell€46,280	Jonathan Zalevsky	Individual	51,115	€0.91
18 Dec 24	Sell€125,633	Howard Robin	Individual	132,030	€0.96
19 Nov 24	Sell€6,111	Mark Wilson	Individual	6,407	€0.95
19 Nov 24	Sell€7,426	Jonathan Zalevsky	Individual	7,785	€0.95
19 Nov 24	Sell€15,527	Howard Robin	Individual	16,278	€0.95
19 Aug 24	Sell€17,221	Howard Robin	Individual	14,881	€1.16
19 Aug 24	Sell€6,540	Mark Wilson	Individual	5,651	€1.16
19 Aug 24	Sell€7,946	Jonathan Zalevsky	Individual	6,866	€1.16
17 May 24	Sell€26,801	Howard Robin	Individual	16,650	€1.61
17 May 24	Sell€10,076	Mark Wilson	Individual	6,260	€1.61
17 May 24	Sell€11,839	Jonathan Zalevsky	Individual	7,355	€1.61
10 May 24	Sell€92,506	Deep Track Capital, LP	Company	56,000	€1.65
20 Feb 24	Sell€5,666	Jonathan Zalevsky	Individual	9,014	€0.63
20 Feb 24	Sell€12,591	Howard Robin	Individual	20,033	€0.63
20 Feb 24	Sell€4,781	Mark Wilson	Individual	7,606	€0.63

Insider Trading Volume

Insider Buying: ITH insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ITH?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	2,710,228	1.47%
VC/PE Firms	15,922,655	8.63%
General Public	40,159,720	21.8%
Institutions	125,665,681	68.1%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 67.32% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
8.66%	BlackRock, Inc.	15,969,345	€17.8m	5.37%	no data
8.63%	Deep Track Capital, LP	15,922,655	€17.7m	-10.9%	0.58%
7.11%	The Vanguard Group, Inc.	13,120,793	€14.6m	1.18%	no data
5.1%	Eventide Asset Management, LLC	9,400,000	€10.5m	24.9%	0.19%
4.99%	Samlyn Capital, LLC	9,199,951	€10.2m	-2.73%	0.17%
3.77%	Citadel Advisors LLC	6,954,970	€7.7m	0%	0.01%
3.21%	PRIMECAP Management Company	5,912,453	€6.6m	-1.79%	no data
3.07%	Acadian Asset Management LLC	5,654,878	€6.3m	15.8%	0.02%
2.74%	Millennium Management LLC	5,061,719	€5.6m	8.63%	no data
2.23%	Nantahala Capital Management, LLC	4,110,000	€4.6m	0%	0.36%
2.17%	TCG Crossover Management, LLC	4,000,000	€4.5m	0%	0.41%
2.15%	Geode Capital Management, LLC	3,963,083	€4.4m	-3.63%	no data
1.81%	State Street Global Advisors, Inc.	3,345,733	€3.7m	11.9%	no data
1.8%	Renaissance Technologies LLC	3,327,633	€3.7m	0.42%	0.01%
1.51%	Jacobs Levy Equity Management Inc	2,793,204	€3.1m	-2.78%	0.01%
1.08%	Monaco Asset Management S.A.M.	1,997,220	€2.2m	-7.81%	0.91%
0.94%	Woodline Partners LP	1,731,671	€1.9m	178%	0.02%
0.94%	Goldman Sachs Group, Investment Banking and Securities Investments	1,726,557	€1.9m	-2.32%	no data
0.86%	Shay Capital LLC	1,595,276	€1.8m	-13.3%	0.49%
0.81%	Two Sigma Advisers, LP	1,500,242	€1.7m	-18.3%	no data
0.79%	Charles Schwab Investment Management, Inc.	1,454,168	€1.6m	-2.26%	no data
0.76%	Northern Trust Global Investments	1,402,158	€1.6m	212%	no data
0.74%	Two Sigma Investments, LP	1,363,170	€1.5m	-24.7%	no data
0.74%	Bridgeway Capital Management, LLC	1,362,100	€1.5m	0%	0.03%
0.71%	Ikarian Capital, LLC	1,312,405	€1.5m	0%	0.44%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/10 00:29
End of Day Share Price	2025/01/10 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nektar Therapeutics is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Richard Silver	Barclays
Aydin Huseynov	Benchmark Company
George Farmer	BMO Capital Markets Equity Research